Drugs / CHF6467
CHF6467
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04077671 | Oct 2018 → Jan 2021 | ulcer of lower limbs | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05733572 | Jun 2023 → Jun 2026 overdue | optic pathway glioma | Benedetto Falsini | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07163182 Comparator | Sep 2025 → Aug 2026 overdue | — | Chiesi Farmaceutici S.p.A. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF6467 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07163182 ↗ |
| Known as | hNGF P61S R100E | “CHF6467 (hNGF P61S R100E; hNGFp), is a recombinant and "painless" form of human NGF.” NCT05733572 ↗ |
| Known as | hNGFp | “CHF6467 (hNGF P61S R100E; hNGFp), is a recombinant and "painless" form of human NGF.” NCT05733572 ↗ |
| Modality | Protein / enzyme biologic | “CHF6467, is mutated form of the human Nerve Growth Factor (NGF).” NCT04077671 ↗ |
| Route | Topical | “multiple days' topical dosing with CHF6467” NCT04077671 ↗ |